HCHarshika Khaim Chandani

Harshika Khaim Chandani

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Harshika Khaim Chandani has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Acute quadriparesis revealing Gitelman syndrome: a case report

    by Harshika Khaim Chandani, Aasiya Ather, Erum Siddiqui, Muhammad Saad Khan, Devya Khaim Chandani, Abubakr Mahmoud

    Introduction and importance: Gitelman syndrome (GS) is a rare autosomal recessive renal tubulopathy caused by SLC12A3 gene mutations, leading to hypokalemia, metabolic alkalosis, hypomagnesemia, and hypocalciuria. Its estimated prevalence ranges from 1 to 10 per 40 000 individuals worldwide, with a carrier frequency approaching 1%, underscoring its potential public health relevance despite underdiagnosis. This case highlights a rare presentation of GS with acute quadriparesis mimicking neurological emergencies, emphasizing the risk of misdiagnosis in acute care settings. Case presentation: A 30-year-old female presented with acute-onset fever, vomiting, and progressive quadriparesis. Examination revealed flaccid paralysis (power: 2/5), areflexia, and bulbar weakness. Critical biochemical findings included severe hypokalemia (K + : 1.6 mmol/l), hypomagnesemia (1.19 mg/dl), metabolic alkalosis (pH: 7.48, HCO 3 − : 32 mEq/l), hypocalciuria (6.43 mg/24 h), low urinary potassium, and elevated serum renin. Clinical discussion: This case demonstrates an intercurrent illness that precipitated acute decompensation in previously undiagnosed GS, leading to profound weakness mimicking Guillain–Barré syndrome, periodic paralysis and Bartter syndrome. The key to diagnosis lies in recognizing the distinctive biochemical triad of hypokalemia, hypomagnesemia, and hypocalciuria with renal potassium wasting. Although genetic testing for SLC12A3 mutations remains the diagnostic gold standard, it is often unavailable in resource-limited settings, making biochemical recognition crucial. Conclusion: GS is a great mimicker that can present with acute severe paralysis. Clinicians must include it in the differential for unexplained hypokalemia and metabolic alkalosis, as prompt recognition and management with magnesium and potassium supplementation are crucial to prevent life-threatening arrhythmias, recurrent paralysis and reduce long-term morbidity.

  • Open Access

    Garadacimab and the future of hereditary angioedema prophylaxis: a step upstream in the bradykinin pathway

    by Harshika Khaim Chandani, Syeda Fadak Zahra Hujjat, Devya Khaim Chandani, Muhammad Saad Khan, Abubakr Mahmoud

    Hereditary angioedema (HAE) is a rare autosomal dominant disorder characterized by recurrent, potentially life-threatening episodes of bradykinin-mediated angioedema affecting the skin, gastrointestinal tract, and upper airway. Despite the availability of several prophylactic therapies, there is a need for effective and convenient treatment options. On 21 June 2024, the U.S. Food and Drug Administration approved Andembry™ (garadacimab-gxii), a first-in-class monoclonal antibody that inhibits activated Factor XII (FXIIa), for prophylaxis of HAE attacks in patients aged ≥12 years. By targeting FXIIa, garadacimab acts upstream in the kallikrein–kinin pathway, suppressing bradykinin generation and preventing vascular permeability associated with angioedema. Clinical trials demonstrated substantial reductions in attack frequency, with the phase 3 VANGUARD study reporting a 91.5% reduction in HAE attacks and that approximately 77% of patients remain attack-free during the study period. Garadacimab is administered as a 200-mg subcutaneous injection once monthly and has a favorable pharmacokinetic profile with an elimination half-life of approximately 18–20 days. Adverse events were generally mild, including headache, nasopharyngitis, and injection-site reactions. The approval of garadacimab represents an important advancement in HAE prophylaxis, offering a novel upstream mechanism, convenient dosing, and potential improvement in quality of life of the patients.

  • Retracted
    Open Access

    Enflonsia (clesrovimab) and the future of RSV lower respiratory tract disease prevention in neonates

    by Harshika K. Chandani, Syeda F. Zahra Hujjat, Devya K. Chandani, Muhammad S. Khan, Abubakr Mahmoud

    Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract disease in infants, with the highest burden in those under 6 months of age. Global RSV epidemics occur seasonally and nearly all children are infected within the age of 2 years, resulting in significant hospitalizations, morbidity, and healthcare costs. Enflonsia™ (clesrovimab-cfor), recently approved by the U.S. Food and Drug Administration, is a long-acting recombinant monoclonal antibody targeting the prefusion F protein of RSV, preventing viral entry and replication. A single intramuscular dose provides protection across the RSV season, eliminating the need for monthly injections. Clinical trials indicate that clesrovimab reduces RSV-related hospitalizations by up to 76% and medically attended RSV disease by over 70%, with a safety profile comparable to existing antibodies like palivizumab and nirsevimab. Common adverse events include mild injection-site reactions and rare hypersensitivity. While its high cost and cold-chain requirements may limit accessibility in low- and middle-income countries, the single-dose, season-long protection offers logistical advantages and potential cost-effectiveness in high-burden settings. Enflonsia represents a significant advance in infant RSV prophylaxis, with implications for global health strategies, integration into immunization programs, and equitable access to reduce RSV morbidity worldwide.

  • Open Access

    Jascayd (nerandomilast): a novel PDE4B inhibitor for idiopathic pulmonary fibrosis

    by Syeda Fadak Zahra Hujjat, Harshika Khaim Chandani, Devya Khaim Chandani, Muhammad Saad Khan, Abubakr Mahmoud

    Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial pneumonia with poor prognosis and limited therapeutic options. Despite the introduction of pirfenidone and nintedanib, treatment discontinuation due to adverse effects remains common, highlighting the need for better-tolerated, mechanistically distinct agents. Jascayd (nerandomilast), a first-in-class selective phosphodiesterase-4B inhibitor developed by Boehringer Ingelheim, was approved by the FDA in October 2025 for adults with IPF. By elevating intracellular cyclic adenosine monophosphate (cAMP) in inflammatory and structural lung cells, nerandomilast suppresses pro-inflammatory cytokines and fibroblast activation, producing anti-inflammatory and antifibrotic effects with improved tolerability over nonselective PDE4 inhibitors. In phase 3 FIBRONEER-IPF and FIBRONEER-ILD trials, nerandomilast significantly reduced the annual rate of forced vital capacity decline versus placebo, regardless of concomitant antifibrotic use. Common adverse effects included mild diarrhea, nausea, and fatigue, with low discontinuation rates. Long-term extension data demonstrate sustained safety and lung function preservation. Offering both monotherapy and combination potential, Jascayd establishes a new therapeutic class that targets inflammation and fibrosis concurrently, representing a pivotal advancement toward personalized, multi-pathway treatment in IPF.


  • Open Access

    Metabolic miracle or misguided shift? Tirzepatide in the era of obstructive sleep apnea (OSA)

    by Devya Khaim Chandani, Harshika Khaim Chandani, Muhammad Saad Khan, Syeda Fadak Zahra Hujjat, Aminath Waafira

    Obstructive sleep apnoea (OSA) is a prevalent disorder marked by recurrent upper airway obstruction during sleep, often linked to obesity and poor continuous positive airway pressure (CPAP) adherence. Tirzepatide, a dual GIP and GLP-1 receptor agonist approved for weight loss, has garnered interest as a potential pharmacologic option for OSA due to its weight-reducing effects. While early studies show modest reductions in apnoea-hypopnoea index and improved sleep quality, these benefits are indirect and fail to address the anatomical basis of OSA. Moreover, concerns about long-term efficacy, weight regain post-discontinuation, and adverse effects such as gastrointestinal symptoms and pancreatitis limit its standalone use. Tirzepatide may complement, but not replace, first-line therapies like CPAP. Future research should assess its role within integrated treatment models and clarify its impact on airway mechanics. Caution is warranted to avoid overreliance on pharmacologic solutions at the expense of established, effective interventions in managing this multifactorial condition. Further research should evaluate the integrated models that combine pharmaceutical therapy with lifestyle and mechanical therapies, investigate the direct impact on airway mechanics, and use the artificial intelligence to identify responders and optimize personalized treatment strategies.


  • Open Access

    Bruton’s tyrosine kinase inhibition in ITP: Wayrilz (rilzabrutinib) as a disease-modifying strategy

    by Syeda Fadak Zahra Hujjat, Harshika Khaim Chandani, Muhammad Saad Khan, Devya Khaim Chandani, Abubakr Mahmoud

    Immune thrombocytopenia (ITP) is an acquired autoimmune disorder characterized by immune-mediated platelet destruction and impaired platelet production, leading to bleeding risk, morbidity, and reduced quality of life. Incomplete responses, adverse effects, and relapses are the limitations of current treatments, which include corticosteroids, intravenous immunoglobulin, rituximab, and thrombopoietin receptor agonists. On 29 August 2025, the U.S. Food and Drug Administration (FDA) approved Wayrilz (rilzabrutinib), a first-in-class oral Bruton’s tyrosine kinase inhibitor, for the treatment of adult patients with chronic or persistent ITP who have had an insufficient response to previous treatments. Through modulation of both Fc receptor and B-cell receptor signaling, the agent aims to address disease pathophysiology as a treatment that is disease-modifying in nature rather than simplistically dealing with symptoms. Clinical trials, including the key LUNA 3 trial, have shown good efficacy and safety, with durable platelet responses and minimal severe adverse events. This editorial examines rilzabrutinib’s scientific justification, clinical data, comparative analysis, side effects, financial ramifications, and potential applications in the treatment of ITP.


  • Open Access

    From dietary restriction to disease-targeted therapy: Sephience TM (sepiapterin) in phenylketonuria

    by Harshika Khaim Chandani, Sahira, Syeda Fadak Zahra Hujjat, Muhammad Saad Khan, Abubakr Mahmoud

    Phenylketonuria (PKU) is a rare metabolic disorder caused by deficient phenylalanine hydroxylase, leading to toxic phenylalanine buildup and severe neurodevelopmental consequences if untreated. Despite advances in newborn screening and dietary management, treatment options remain limited and burdensome. The recent FDA approval of Sephience (sepiapterin) marks a major advancement in PKU care. Sepiapterin, a precursor of tetrahydrobiopterin (BH₄), enhances enzyme activity and stability, offering therapeutic benefit even in patients unresponsive to BH₄ alone. Results from the pivotal APHENITY Phase III trial demonstrated a substantial 63% mean reduction in blood phenylalanine and significant dietary liberalization, with 97% of participants able to increase natural protein intake safely. Importantly, 43% of prior non-responders to sapropterin showed clinical improvement, highlighting its potential to address key gaps in PKU management. With broad approval for children and adults, Sephience provides a disease-targeted therapy that extends beyond dietary restriction. While careful monitoring for adverse effects such as gastrointestinal symptoms and hypophenylalaninemia is required, this approval represents a transformative step in precision medicine. Sephience has the potential to redefine the standard of care and improve long-term quality of life for individuals living with PKU.


  • Open Access

    Harliku (nitisinone): first FDA-approved disease-modifying therapy for alkaptonuria

    by Harshika Khaim Chandani, Syeda Fadak Zahra Hujjat, Devya Khaim Chandani, Muhammad Saad Khan, Abubakr Mahmoud

    Alkaptonuria (AKU) is a rare autosomal recessive metabolic disorder due to a deficiency of homogentisate 1,2-dioxygenase, subsequently leading to the progressive acquisition of ochronosis, osteoarthropathy, systemic complications, and the pathological retention of homogentisic acid (HGA). Until recently, apart from supportive management which involved orthopedic surgery and symptomatic treatment, there was no attempt to slow the progress of the disease. On 19 June 2025, the U.S. Food and Drug Administration approved Harliku (nitisinone) as the first therapy to modify the progression of the disease. As a competitive inhibitor of 4-hydroxyphenylpyruvate dioxygenase, nitisinone exerts biochemical efficacy with a greater than 95% reduction of urinary excretion of HGA. The SONIA 2 and other studies funded by the NIH have demonstrated long-standing metabolic control with nitisinone, as well as improved functional outcomes and possibly cardioprotective effects. Although the evidence of long-term benefits is promising, risks of treatment, such as tyrosinemia, require attention to diet and continued monitoring. As the first single agent to be taken orally once daily, Harliku changes the paradigm of management for the rare metabolic disorder AKU from symptomatic treatment to disease-modifying therapy. It is a huge leap for other disorders of metabolism and paves the way for future innovations in therapy.

  • Open Access

    Pulmonary arterial hypertension and the limits of convenience: a critical look at yutrepia

    by Devya Khaim Chandani, Arisha Issa, Harshika Khaim Chandani, Sarah Qureshi, Erum Siddiqui, Abubakr Mahmoud

  • Open Access

    Breaking barriers in HIV management: the rise of long-acting lenacapavir

    by Devya Khaim Chandani, Sahira Khan, Harshika Khaim Chandani, Muhammad Saad Khan, Abubakr Mahmoud

    Human immunodeficiency virus type 1 (HIV-1) remains a global health challenge, affecting over 38 million people as of 2024. The recent FDA approval of lenacapavir (Yeztugo®) on 18 June 2025 marks a significant advance in prevention and treatment. Lenacapavir is the first-in-class, long-acting HIV-1 capsid inhibitor, administered twice yearly via subcutaneous injection for pre-exposure prophylaxis in adults and adolescents ≥35 kg. It targets the capsid protein, disrupting multiple stages of the viral lifecycle without cross-resistance to existing antiretrovirals. Clinical trials (CAPELLA, CALIBRATE) demonstrated robust efficacy, with up to 94% viral suppression when combined with active agents and sustained CD4+ gains. Its prolonged half-life, minimal drug–drug interactions, and convenient dosing improve adherence, privacy, and healthcare access – critical in high-incidence, resource-limited settings. Ongoing PURPOSE trials are evaluating its role in high-risk populations. Lenacapavir’s favorable safety profile and public health potential support its integration into evolving HIV management and prevention strategies, potentially accelerating progress toward epidemic control.